BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by left ventricular hypertrophy in the absence of other etiologies. Clinical presentation may vary from asymptomatic to sudden cardiac death. Medical treatment is the first-line therapy for symptomatic patients. Extended left ventricular septal myectomy is the procedure of choice if medical treatment is unsuccessful or intolerable. MAYO CLINIC EXPERIENCE: More than 3,000 patients have had septal myectomy for HCM at the Mayo Clinic (MN, USA) from 1993 to 2016. Risk of hospital death after isolated septal myectomy for obstructive HCM is <1% and is similar to the risk of operation for elective mitral valve repair. Complications, such as complete heart block requiring permanent pacemaker, are uncommon (2%), although partial or complete left bundle branch block is a frequent finding on the postoperative ECG. Relief of left ventricular outflow tract (LVOT) obstruction with septal myectomy dramatically improves symptoms and exercise capacity in symptomatic patients with obstructive HCM. More than 90% of severely symptomatic patients have improvement by at least two functional classes, and reduction of outflow gradients by myectomy decreases or eliminates symptoms of dyspnea, angina and/or syncope. Basal obstruction with systolic anterior motion (SAM) is treated by transaortic myectomy. The transapical approach was applied in 115 patients with obstructive midventricular and apical variants of HCM between 1993 and 2012. All patients with midventricular obstruction had gradient relief and none developed an apical aneurysm or ventricular septal defect. Recurrent obstruction after satisfactory myectomy was rare. CONCLUSIONS: Septal myectomy effectively and definitively relieves LVOT obstruction and cardiac symptoms in patients with obstructive HCM. In experienced centers, early mortality for isolated septal myectomy is less than 1%, and overall results are excellent and continue to improve in the current era.
BACKGROUND:Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by left ventricular hypertrophy in the absence of other etiologies. Clinical presentation may vary from asymptomatic to sudden cardiac death. Medical treatment is the first-line therapy for symptomatic patients. Extended left ventricular septal myectomy is the procedure of choice if medical treatment is unsuccessful or intolerable. MAYO CLINIC EXPERIENCE: More than 3,000 patients have had septal myectomy for HCM at the Mayo Clinic (MN, USA) from 1993 to 2016. Risk of hospital death after isolated septal myectomy for obstructive HCM is <1% and is similar to the risk of operation for elective mitral valve repair. Complications, such as complete heart block requiring permanent pacemaker, are uncommon (2%), although partial or complete left bundle branch block is a frequent finding on the postoperative ECG. Relief of left ventricular outflow tract (LVOT) obstruction with septal myectomy dramatically improves symptoms and exercise capacity in symptomatic patients with obstructive HCM. More than 90% of severely symptomatic patients have improvement by at least two functional classes, and reduction of outflow gradients by myectomy decreases or eliminates symptoms of dyspnea, angina and/or syncope. Basal obstruction with systolic anterior motion (SAM) is treated by transaortic myectomy. The transapical approach was applied in 115 patients with obstructive midventricular and apical variants of HCM between 1993 and 2012. All patients with midventricular obstruction had gradient relief and none developed an apical aneurysm or ventricular septal defect. Recurrent obstruction after satisfactory myectomy was rare. CONCLUSIONS: Septal myectomy effectively and definitively relieves LVOT obstruction and cardiac symptoms in patients with obstructive HCM. In experienced centers, early mortality for isolated septal myectomy is less than 1%, and overall results are excellent and continue to improve in the current era.
Authors: Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy Journal: J Thorac Cardiovasc Surg Date: 2011-12 Impact factor: 5.209
Authors: Hartzell V Schaff; Morgan L Brown; Joseph A Dearani; Martin D Abel; Steve R Ommen; Paul Sorajja; A Jamil Tajik; Rick A Nishimura Journal: J Thorac Cardiovasc Surg Date: 2010-03 Impact factor: 5.209
Authors: Steve R Ommen; Barry J Maron; Iacopo Olivotto; Martin S Maron; Franco Cecchi; Sandro Betocchi; Bernard J Gersh; Michael J Ackerman; Robert B McCully; Joseph A Dearani; Hartzell V Schaff; Gordon K Danielson; A Jamil Tajik; Rick A Nishimura Journal: J Am Coll Cardiol Date: 2005-08-02 Impact factor: 24.094
Authors: Hyun Suk Yang; Kwan S Lee; Hari P Chaliki; Henry D Tazelaar; Joan L Lusk; Krishnaswamy Chandrasekaran; A Jamil Tajik Journal: Eur J Echocardiogr Date: 2008-07-11
Authors: Paul Sorajja; Uma Valeti; Rick A Nishimura; Steve R Ommen; Charanjit S Rihal; Bernard J Gersh; David O Hodge; Hartzell V Schaff; David R Holmes Journal: Circulation Date: 2008-07-08 Impact factor: 29.690
Authors: Su Min Chang; Nasser M Lakkis; Jennifer Franklin; William H Spencer; Sherif F Nagueh Journal: Circulation Date: 2004-02-16 Impact factor: 29.690
Authors: Sara Ranjbarvaziri; Kristina B Kooiker; Mathew Ellenberger; Giovanni Fajardo; Mingming Zhao; Alison Schroer Vander Roest; Rahel A Woldeyes; Tiffany T Koyano; Robyn Fong; Ning Ma; Lei Tian; Gavin M Traber; Frandics Chan; John Perrino; Sushma Reddy; Wah Chiu; Joseph C Wu; Joseph Y Woo; Kathleen M Ruppel; James A Spudich; Michael P Snyder; Kévin Contrepois; Daniel Bernstein Journal: Circulation Date: 2021-10-21 Impact factor: 39.918
Authors: Victor Arévalos; Juan José Rodríguez-Arias; Salvatore Brugaletta; Antonio Micari; Francesco Costa; Xavier Freixa; Mónica Masotti; Manel Sabaté; Ander Regueiro Journal: J Clin Med Date: 2021-05-24 Impact factor: 4.241